VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!
×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Non-Hodgkin Lymphoma
Kristie L. Kahl
In this week’s episode of CURETalks Cancer, we spoke with Matt Lashey, creator and CEO of the chemoWave app, which is designed to manage cancer symptoms and conditions by keeping track of a patient’s overall well-being to understand how their experiences may be related to feeling better or worse during treatment.
Jessica Skarzynski
Thanks to genomic analysis by scientists at the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard, diffuse large B cell lymphoma (DLBCL) is now a little easier to understand – and possibly easier to treat.
Shira Zwebner
Cancer has a profound effect on the youngest members of the family, especially when you go from swim Mom to sick Mom overnight.
Ron Hawkins
Kristie L. Kahl
The chemoWave app, launched in July 2017, is designed to manage cancer symptoms and conditions by keeping track of a patient’s overall well-being.
Beth Incollingo
Yescarta was granted FDA approval for use in adults with relapsed or refractory non-Hodgkin lymphoma. This is only the second CAR T-cell therapy ever approved.
Allie Casey
Jessica Yasmine Islam, M.P.H., discusses the changing statistics behind people with HIV and cancer.
Danielle Bucco
Leo I. Gordon, M.D., discusses an exciting new trial for patients with non-Hodgkin lymphoma.
Silas Inman
A recent phase 3 study showed that Imbruvica plus ublituximab may be a promising option for some patients with CLL.